Clinical Trial Update: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and efficacy of switching from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Eylea) (aflibercept)
• Ranibizumab (Lucentis) (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2019-02-15